Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 229 matching drugs for APP — including drugs targeting any of its 48 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
disulfiram, copper, alkylating agents APP Direct 1
binimetinib and encorafenib BRAF SSL via BRAF yes 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NTRK1 SSL via NTRK1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RAF1 SSL via RAF1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) NTRK1 SSL via NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RAF1 SSL via RAF1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LYN SSL via LYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib NTRK1 SSL via NTRK1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib RAF1 SSL via RAF1 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
abemaciclib CDK4 SSL via CDK4 yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel RAF1 SSL via RAF1 2
alvocidib, paclitaxel CDK4 SSL via CDK4 2
alvocidib, paclitaxel CDK5 SSL via CDK5 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LYN SSL via LYN 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 2
bryostatin 1, paclitaxel PRKCA SSL via PRKCA 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK4 SSL via CDK4 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib NTRK1 SSL via NTRK1 2
everolimus MTOR SSL via MTOR yes 2
nintedanib LYN SSL via LYN 2
nintedanib, pembrolizumab LYN SSL via LYN 2
palbociclib CDK4 SSL via CDK4 yes 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib NTRK1 SSL via NTRK1 2
regorafenib RAF1 SSL via RAF1 yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
regorafenib, laboratory biomarker analysis NTRK1 SSL via NTRK1 2
regorafenib, laboratory biomarker analysis RAF1 SSL via RAF1 2
sorafenib, administered orally, ct/mri RAF1 SSL via RAF1 2
temsirolimus MTOR SSL via MTOR 2
temsirolimus, laboratory biomarker analysis MTOR SSL via MTOR 2
abemaciclib, abemaciclib CDK4 SSL via CDK4 1
abemaciclib, bevacizumab CDK4 SSL via CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CDK4 SSL via CDK4 1
abemaciclib, ly3023414, gemcitabine, capecitabine CDK4 SSL via CDK4 1
abemaciclib, ly3214996 CDK4 SSL via CDK4 1
abemaciclib, surgery CDK4 SSL via CDK4 1
aee788, everolimus MTOR SSL via MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CDK4 SSL via CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib LYN SSL via LYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib MTOR SSL via MTOR 1
alpelisib, everolimus, exemestane MTOR SSL via MTOR 1
alvocidib, docetaxel CDK4 SSL via CDK4 1
alvocidib, docetaxel CDK5 SSL via CDK5 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK4 SSL via CDK4 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK5 SSL via CDK5 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib CDK4 SSL via CDK4 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib MTOR SSL via MTOR 1
arsenic trioxide IKBKB SSL via IKBKB 1
arsenic trioxide, radiation therapy IKBKB SSL via IKBKB 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy IKBKB SSL via IKBKB 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus MTOR SSL via MTOR 1
bevacizumab, dasatinib, placebo ABL1 SSL via ABL1 1
bevacizumab, dasatinib, placebo FYN SSL via FYN 1
bevacizumab, dasatinib, placebo LYN SSL via LYN 1
bevacizumab, everolimus, octreotide acetate MTOR SSL via MTOR 1
bevacizumab, temsirolimus MTOR SSL via MTOR 1
biopsy, biospecimen collection, computed tomography, larotrectinib, magnetic resonance imaging NTRK1 SSL via NTRK1 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 1
blu-222, carboplatin, ribociclib, fulvestrant CDK4 SSL via CDK4 1
bosutinib ABL1 SSL via ABL1 yes 1
bosutinib LYN SSL via LYN 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab CDK4 SSL via CDK4 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LYN SSL via LYN 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin IKBKB SSL via IKBKB 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
cisplatin, pemetrexed disodium, sorafenib RAF1 SSL via RAF1 1
conventional surgery, laboratory biomarker analysis, sorafenib tosylate, temsirolimus MTOR SSL via MTOR 1
cytoreductive surgery, perifosine, temsirolimus MTOR SSL via MTOR 1
cytoreductive surgery, perifosine, temsirolimus PRKCA SSL via PRKCA 1
dabrafenib, trametinib RAF1 SSL via RAF1 1
dabrafenib, trametinib, carboplatin, vincristine RAF1 SSL via RAF1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride ABL1 SSL via ABL1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FYN SSL via FYN 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LYN SSL via LYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method ABL1 SSL via ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FYN SSL via FYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LYN SSL via LYN 1
dasatinib, laboratory biomarker analysis, physiologic testing ABL1 SSL via ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing FYN SSL via FYN 1
dasatinib, laboratory biomarker analysis, physiologic testing LYN SSL via LYN 1
dasatinib, mfolfox6 ABL1 SSL via ABL1 1
dasatinib, mfolfox6 FYN SSL via FYN 1
dasatinib, mfolfox6 LYN SSL via LYN 1
dasatinib, pharmacological study ABL1 SSL via ABL1 1
dasatinib, pharmacological study FYN SSL via FYN 1
dasatinib, pharmacological study LYN SSL via LYN 1
dasatinib, temozolomide, placebo, radiation therapy ABL1 SSL via ABL1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.